Premium
Pilot study to evaluate the safety and therapeutic efficacy of topical oxifulvic acid in atopic volunteers
Author(s) -
Snyman J.R.,
Dekker J.,
Malfeld S.C.K.,
van Rensburg C.E.J.
Publication year - 2002
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.10116
Subject(s) - medicine , placebo , volunteer , sensitization , allergy , sensitive skin , atopic dermatitis , hydrocortisone , randomized controlled trial , erythema , house dust mite , allergen , pharmacology , anesthesia , gastroenterology , dermatology , immunology , pathology , alternative medicine , agronomy , biology
Abstract The study objectives were to establish first the safety and second the therapeutic efficacy of topically applied oxifulvic acid compared to 1% hydrocortisone and placebo creams. Oxifulvic acid has established antiinflammatory properties in vitro. It also inhibits elicited ear inflammation in mice at concentrations of 4.5 and 9%. In this double‐blind cross‐over study, 23 healthy volunteers allergic to grass or house dust mite allergen were recruited and included after signing informed consent. During the initial run‐in period all volunteers were randomized to apply either 4.5 or 9% oxifulvic acid for 2 weeks on the volare aspect of one forearm (100 mm diameter) and rechallenged 21 days later to establish sensitization. Thereafter, volunteers were randomized to either placebo. 1% hydrocortisone, 4.5 or 9% oxifulvic acid creams. Creams were applied under occlusions 1 h prior to intradermal allergen challenge and every 8 h thereafter for 3 days (21‐day intervals). The surface areas of the immediate and late phase skin reactions were calculated. Liver and kidney function tests as well as full blood counts were done at screening and thereafter weekly for the first 2 weeks and then at each follow‐up visit. Topically applied oxifulvic acid had no significant effect on any of the safety parameters and also did not induce sensitization when applied on the skin. Oxifulvic acid (4.5%) caused inhibition of the elicited inflammatory reaction at 15 min and differed significantly from the 9% cream at 24 h. These changes were similar to that caused by hydrocortisone. No other significant changes were detected. Drug Dev. Res. 57:40–43, 2002. © 2002 Wiley‐Liss, Inc.